Cargando…

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer

The onset of brain metastases (BM) is a major turning point during advanced breast cancer (ABC) evolution, with only few treatment options when local therapies have failed. The therapeutic effect of eribulin, a wildly used drug in the treatment of ABC, remains unclear in this setting. Patients and M...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabatier, Renaud, Martin, Johan, Vicier, Cécile, Guérin, Mathilde, Monneur, Audrey, Provansal, Magali, Tassy, Louis, Tarpin, Carole, Extra, Jean-Marc, Viret, Frédéric, Goncalves, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003126/
https://www.ncbi.nlm.nih.gov/pubmed/33803894
http://dx.doi.org/10.3390/jcm10061272
_version_ 1783671616588218368
author Sabatier, Renaud
Martin, Johan
Vicier, Cécile
Guérin, Mathilde
Monneur, Audrey
Provansal, Magali
Tassy, Louis
Tarpin, Carole
Extra, Jean-Marc
Viret, Frédéric
Goncalves, Anthony
author_facet Sabatier, Renaud
Martin, Johan
Vicier, Cécile
Guérin, Mathilde
Monneur, Audrey
Provansal, Magali
Tassy, Louis
Tarpin, Carole
Extra, Jean-Marc
Viret, Frédéric
Goncalves, Anthony
author_sort Sabatier, Renaud
collection PubMed
description The onset of brain metastases (BM) is a major turning point during advanced breast cancer (ABC) evolution, with only few treatment options when local therapies have failed. The therapeutic effect of eribulin, a wildly used drug in the treatment of ABC, remains unclear in this setting. Patients and Methods: We performed a retrospective observational study to assess eribulin efficacy in patients with ABC who displayed BM at time of eribulin initiation. We collected data from the medical files of all ABC patients who received eribulin at our institution from 2012 until 2020. Our main endpoint was the central nervous system (CNS) progression-free survival. (CNS-PFS). Other evaluation criteria were extra-cranial progression free survival (PFS) and overall survival (OS). Results: Twenty patients with BM monitoring data available were selected out of the 549 who received eribulin during the inclusion period. Fifteen patients (75%) had BM progressive as the best response, three patients (15%) had disease stabilization for more than 6 months and only one patient had a partial response according to RECIST 1.1 criteria. Median CNS-PFS was 3.39 months (95CI (3.02–3.76)). Cox univariate analysis identified molecular subtype as the only prognostic parameter in our cohort, with patients with hormone-receptor positive tumors less likely to experience CNS progression than those with triple-negative MBC (HR = 0.23 (95CI = 0.07–0.80), p = 0.021). Median extra-cranial PFS was 2.67 months (95CI (2.33–3.01)). Median OS was 7.68 months (95CI (0–17.41)). Conclusion: Eribulin seems to have only a limited impact on BM evolution. Hormone receptors expression may identify a subset of patients with better BM control.
format Online
Article
Text
id pubmed-8003126
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80031262021-03-28 Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer Sabatier, Renaud Martin, Johan Vicier, Cécile Guérin, Mathilde Monneur, Audrey Provansal, Magali Tassy, Louis Tarpin, Carole Extra, Jean-Marc Viret, Frédéric Goncalves, Anthony J Clin Med Article The onset of brain metastases (BM) is a major turning point during advanced breast cancer (ABC) evolution, with only few treatment options when local therapies have failed. The therapeutic effect of eribulin, a wildly used drug in the treatment of ABC, remains unclear in this setting. Patients and Methods: We performed a retrospective observational study to assess eribulin efficacy in patients with ABC who displayed BM at time of eribulin initiation. We collected data from the medical files of all ABC patients who received eribulin at our institution from 2012 until 2020. Our main endpoint was the central nervous system (CNS) progression-free survival. (CNS-PFS). Other evaluation criteria were extra-cranial progression free survival (PFS) and overall survival (OS). Results: Twenty patients with BM monitoring data available were selected out of the 549 who received eribulin during the inclusion period. Fifteen patients (75%) had BM progressive as the best response, three patients (15%) had disease stabilization for more than 6 months and only one patient had a partial response according to RECIST 1.1 criteria. Median CNS-PFS was 3.39 months (95CI (3.02–3.76)). Cox univariate analysis identified molecular subtype as the only prognostic parameter in our cohort, with patients with hormone-receptor positive tumors less likely to experience CNS progression than those with triple-negative MBC (HR = 0.23 (95CI = 0.07–0.80), p = 0.021). Median extra-cranial PFS was 2.67 months (95CI (2.33–3.01)). Median OS was 7.68 months (95CI (0–17.41)). Conclusion: Eribulin seems to have only a limited impact on BM evolution. Hormone receptors expression may identify a subset of patients with better BM control. MDPI 2021-03-18 /pmc/articles/PMC8003126/ /pubmed/33803894 http://dx.doi.org/10.3390/jcm10061272 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sabatier, Renaud
Martin, Johan
Vicier, Cécile
Guérin, Mathilde
Monneur, Audrey
Provansal, Magali
Tassy, Louis
Tarpin, Carole
Extra, Jean-Marc
Viret, Frédéric
Goncalves, Anthony
Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
title Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
title_full Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
title_fullStr Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
title_full_unstemmed Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
title_short Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
title_sort eribulin efficacy on brain metastases in heavily pretreated patients with metastatic breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003126/
https://www.ncbi.nlm.nih.gov/pubmed/33803894
http://dx.doi.org/10.3390/jcm10061272
work_keys_str_mv AT sabatierrenaud eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer
AT martinjohan eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer
AT viciercecile eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer
AT guerinmathilde eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer
AT monneuraudrey eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer
AT provansalmagali eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer
AT tassylouis eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer
AT tarpincarole eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer
AT extrajeanmarc eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer
AT viretfrederic eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer
AT goncalvesanthony eribulinefficacyonbrainmetastasesinheavilypretreatedpatientswithmetastaticbreastcancer